Founded in 1987, Clinuvel is headquartered in Melbourne, Australia and has operations in Europe, Asia, and the United States. The company's flagship product, SCENESSE, is a first-of-its-kind photoprotective drug that is designed to treat patients with the genetic disorder, erythropoietic protoporphyria (EPP). SCENESSE, which was approved by the European Medicines Agency (EMA) in 2014, has significantly improved the quality of life for EPP patients by reducing their sensitivity to light and allowing them to engage in outdoor activities. Clinuvel has a strong pipeline of products, including treatments for genetic disorders such as xeroderma pigmentosum (XP) and metabolic disorders such as phenylketonuria (PKU). The company's goal is to expand its market reach and offer more solutions for patients with rare and underserved diseases around the world.